Arcutis Biotherapeutics Inc (NASDAQ: ARQT) is 165.94% higher on its value in year-to-date trading and has touched a low of $1.76 and a high of $13.17 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ARQT stock was last observed hovering at around $8.88 in the last trading session, with the day’s loss setting it -0.29%.
Currently trading at $8.59, the stock is -0.69% and -9.24% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.61 million and changing -3.27% at the moment leaves the stock 35.49% off its SMA200. ARQT registered 2.26% gain for a year compared to 6-month gain of 338.27%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -2.16% loss in the last 1 month and extending the period to 3 months gives it a -17.48%, and is -9.39% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.56% over the week and 8.27% over the month.
Arcutis Biotherapeutics Inc (ARQT) has around 296 employees, a market worth around $994.38M and $106.39M in sales. Profit margin for the company is -204.36%. Distance from 52-week low is 388.07% and -34.78% from its 52-week high. The company has generated returns on investments over the last 12 months (-50.45%).
The EPS is expected to grow by 55.07% this year
The shares outstanding are 96.79M, and float is at 90.28M with Short Float at 24.56%.
Arcutis Biotherapeutics Inc (ARQT) Insider Activity
The most recent transaction is an insider sale by Matsuda Masaru, the company’s SEC filings show that Matsuda Masaru sold 1,775 shares of the company’s common stock on May 28 ’24 at a price of $9.01 per share for a total of $15988.0. Following the sale, the insider now owns 0.19 million shares.
Arcutis Biotherapeutics Inc disclosed in a document filed with the SEC on May 17 ’24 that Edwards Larry Todd (SVP Chief Commercial Officer) sold a total of 7,640 shares of the company’s common stock. The trade occurred on May 17 ’24 and was made at $8.98 per share for $68582.0. Following the transaction, the insider now directly holds 0.14 million shares of the ARQT stock.
Still, SEC filings show that on May 02 ’24, Watanabe Todd Franklin disposed off 13,783 shares at an average price of $8.74 for $0.12 million. The insider now directly holds 860,750 shares of Arcutis Biotherapeutics Inc (ARQT).
